Background— Liver X receptors (LXRs) are ligand-activated transcription factors involved in the control of lipid metabolism and inflammation. Synthetic LXR agonists have been shown to inhibit the progression of atherosclerosis in mice, but the mechanism is uncertain. LXR agonism upregulates the genes encoding ATP binding cassette transporters A1 (ABCA1) and G1 (ABCG1) in macrophages, thus promoting efflux of cholesterol; it also upregulates liver and intestinal ABCG5 and ABCG8, helping to promote biliary and fecal excretion of cholesterol. Thus, LXR agonism may inhibit atherosclerosis through promotion of reverse cholesterol transport (RCT) in vivo, but this has not been proven. We previously described an in vivo method to trace the movement of cholesterol from ³ H-cholesterol–labeled J774 macrophages into plasma, into liver, and ultimately into the bile and feces as free cholesterol or bile acids. In the present study we used this approach to test the hypothesis that administration of the synthetic LXR agonist GW3965 would increase the rate of macrophage RCT in vivo. Methods and Results— Three different mouse models—wild-type C57BL/6 mice, LDLR/apobec-1 double knockout mice, and human apolipoprotein (apo)B/cholesteryl ester transfer protein (CETP) double transgenic mice—were treated with either vehicle or GW3965. Mice were injected intraperitoneally with ³ H-cholesterol–labeled and cholesterol-loaded macrophages and monitored for the appearance of ³ H-tracer in plasma, liver, and feces. Administration of GW3965 significantly increased the levels of ³ H-tracer in plasma and feces in all 3 mouse models. Conclusions— These results demonstrate that administration of the LXR agonist GW3965 increases the rate of RCT from macrophages to feces in vivo.

Hepatic expression of the scavenger receptor class B type I (SR-BI) promotes selective uptake of HDL cholesterol by the liver and is believed to play a role in the process of reverse cholesterol transport (RCT). We hypothesized that hepatic SR-BI expression is a regulator of the rate of integrated macrophage-to-feces RCT and used an in vivo model to test this hypothesis. Cholesterol-loaded and [³H]cholesterol-labeled J774 macrophages were injected intraperitoneally into mice, after which the appearance of the [³H]cholesterol in the plasma, liver, and feces over 48 hours was quantitated. Mice overexpressing SR-BI in the liver had significantly reduced [³H]cholesterol in the plasma but markedly increased [³H] tracer excretion in the feces over 48 hours. Conversely, mice deficient in SR-BI had significantly increased [³H]cholesterol in the plasma but markedly reduced [³H] tracer excretion in the feces over 48 hours. These studies demonstrate that hepatic SR-BI expression, despite its inverse effects on steady-state plasma HDL cholesterol concentrations, is an important positive regulator of the rate of macrophage RCT.

Background: Mesenchymal stromal cells (MSCs) are multipotent progenitor cells used in several cell therapies. MSCs are characterized by the expression of CD73, CD90, and CD105 cell markers, and the absence of CD34, CD45, CD11a, CD19, and HLA-DR cell markers. CD90 is a glycoprotein present in the MSC membranes and also in adult cells and cancer stem cells. The role of CD90 in MSCs remains unknown. Here, we sought to analyse the role that CD90 plays in the characteristic properties of in vitro expanded human MSCs. Methods: We investigated the function of CD90 with regard to morphology, proliferation rate, suppression of T-cell proliferation, and osteogenic/adipogenic differentiation of MSCs by reducing the expression of this marker using CD90-target small hairpin RNA lentiviral vectors. Results: The present study shows that a reduction in CD90 expression enhances the osteogenic and adipogenic differentiation of MSCs in vitro and, unexpectedly, causes a decrease in CD44 and CD166 expression. Conclusion: Our study suggests that CD90 controls the differentiation of MSCs by acting as an obstacle in the pathway of differentiation commitment. This may be overcome in the presence of the correct differentiation stimuli, supporting the idea that CD90 level manipulation may lead to more efficient differentiation rates in vitro.

Iron oxides that exhibit magnetic properties have been widely studied not only from an academic standpoint, but also for numerous applications in different fields of knowledge, such as biomedical and technological research. In this work, magnetite and maghemite nanoparticles were synthesized by chemical coprecipitation of FeCl₂·4H₂O and FeCl₃·6H₂O (proportion of 1 : 2) in three different cases using two bases (sodium hydroxide and hydroxide ammonium) as precipitants. The chemical coprecipitation method was selected for its simplicity, convenience, reproducibility, and low cost in the use of glassware. The nanostructured materials were characterized by transmission electron microscopy (TEM), X‐ray diffraction (XRD) and magnetometry (VSM). The objective of this work is to study the variation in the morphological characteristics and physical properties of nanoparticles magnetic as a function of the different production processes. As observed by TEM, the materials obtained from the precipitating agent NH₄OH are more uniform than those obtained with NaOH. From XRD pattern analysis, it appears that the obtained materials correspond to magnetite and maghemite and, from magnetometry VSM analysis, show high magnetization as a function of the magnetic field at room temperature, indicating that these materials are superparamagnetic.